Oxybutynin chloride

产品说明书

Print
Chemical Structure| 1508-65-2 同义名 : Oxybutynin hydrochloride; Oxybutynin (hydrochloride); MJ4309-1
CAS号 : 1508-65-2
货号 : A586213
分子式 : C22H32ClNO3
纯度 : 99%
分子量 : 393.95
MDL号 : MFCD00072150
存储条件：

Pure form Sealed in dry,2-8°C

In solvent -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 105 mg/mL(266.53 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H2O: 30 mg/mL(76.15 mM)，配合低频超声助溶
生物活性
靶点

  • mAChR
描述 Oxybutynin HCl is an anticholinergic agent. Oxybutynin inhibited vascular Kv channels in a concentration-dependent manner, with an IC50 value of 11.51 ± 0.38 μmol/L and a Hill coefficient (n) of 2.25 ± 0.12. Oxybutynin inhibited the vascular Kv current in a concentration-dependent manner by influencing the steady-state activation and inactivation curves independent of its anticholinergic effect[3]. The majority of the patients (88.2%) with IBSF (inadequate bladder storage function) were responsive to the 15-mg daily oxybutynin HCl. Oxybutynin HCl in sufficient dosages seems to be effective in the treatment of enuretic patients with IBSF[4]. Oxybutynin seems promising in the management of hot flashes with tolerable side effects in the majority of refractory patients[5]. Oxybutynin 3% gel reduced hyperhidrosis severity and improved health-related quality of life in this small pilot study[6].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT02386072 - Completed - -
NCT00547378 Urinary Incontinence, Urgency-... 展开 >>frequency Overactive Bladder 收起 << Phase 4 Completed - -
NCT00366002 Overactive Bladder (OAB) Phase 4 Completed - -
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.54mL

0.51mL

0.25mL

12.69mL

2.54mL

1.27mL

25.38mL

5.08mL

2.54mL
参考文献

[1]Anderson RU, Mobley D, et al. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group. J Urol. 1999 Jun;161(6):1809-12.

[2]Yarker YE, Goa KL, et al. Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging. 1995 Mar;6(3):243-62.

[3]Li H, Seo MS, An JR, et al. The anticholinergic drug oxybutynin inhibits voltage-dependent K+ channels in coronary arterial smooth muscle cells. Clin Exp Pharmacol Physiol. 2019;46(11):1030-1036

[4]Koşar A, Arikan N, Dinçel C. Effectiveness of oxybutynin hydrochloride in the treatment of enuresis nocturna--a clinical and urodynamic study. Scand J Urol Nephrol. 1999;33(2):115-118

[5]Sexton T, Younus J, Perera F, Kligman L, Lock M. Oxybutynin for refractory hot flashes in cancer patients. Menopause. 2007;14(3 Pt 1):505-509

[6]Nguyen NV, Gralla J, Abbott J, Bruckner AL. Oxybutynin 3% gel for the treatment of primary focal hyperhidrosis in adolescents and young adults. Pediatr Dermatol. 2018;35(2):208-212